Lipopeptide (Pal-GHK-Lipopeptide) Peptide

Pal-GHK-Lipopeptide is a fatty acid-conjugated form of GHK designed for enhanced transdermal delivery. The palmitoyl chain increases lipophilicity, improving penetration through the stratum corneum by 5-10x compared to unconjugated GHK, enabling topical delivery of copper peptide benefits.

Palmitoyl-GHK lipopeptide (Pal-GHK) is a conjugate of the tripeptide glycyl-L-histidyl-L-lysine (GHK) covalently linked to palmitic acid via an amide bond at the N-terminus. The lipid modification fundamentally alters the pharmacokinetic and pharmacodynamic profile of the parent peptide while preserving its intrinsic biological signaling activity. The compound acts through several parallel and interconnected pathways relevant to dermal matrix research.

Enhanced Dermal Penetration via Lipid Modification

Unconjugated GHK is a small, highly hydrophilic tripeptide (MW 340 Da) that, despite its low molecular weight, exhibits poor stratum corneum penetration because of its strong cationic charge at physiological pH. Conjugation with a 16-carbon palmitic acid chain dramatically increases the LogP of the molecule, allowing it to partition into the intercellular lipid lamellae of the stratum corneum. Once partitioned, the lipopeptide diffuses into viable epidermal layers where esterase and amidase activity can liberate the active GHK fragment, or the intact lipopeptide can engage cell-surface targets directly. This penetration enhancement is the principal rationale behind palmitoylation strategies used widely in cosmeceutical peptide research.

TGF-β and Collagen Pathway Modulation

Pal-GHK has been shown in fibroblast culture studies to upregulate transcription of COL1A1 (type I collagen), COL3A1 (type III collagen), and fibronectin. Mechanistically, this is mediated in part through stimulation of the TGF-β/SMAD signaling axis and through direct effects on fibroblast proliferation. Increased deposition of extracellular matrix proteins and glycosaminoglycans (including decorin and hyaluronic acid) has been documented in ex vivo skin explant models.

Copper-Binding and Antioxidant Activity

The parent GHK tripeptide is a well-characterized high-affinity ligand for copper(II), forming the GHK-Cu complex. While palmitoylation occupies the N-terminal amine and reduces direct copper coordination, intracellular cleavage of the palmitoyl group restores GHK's chelating capacity. The liberated GHK-Cu complex is implicated in superoxide dismutase mimetic activity and modulation of reactive carbonyl species, contributing to the antioxidant profile reported in cosmetic research literature.

MMP Inhibition and Anti-Glycation Effects

In photoaged skin models, Pal-GHK has been associated with downregulation of matrix metalloproteinases MMP-1, MMP-2, and MMP-9, which are responsible for collagen and elastin degradation in chronologically and UV-aged skin. The compound also displays anti-glycation activity, inhibiting the formation of advanced glycation end-products (AGEs) that contribute to dermal stiffness and yellowing in aged tissue.

Comparison to Related Lipopeptides

Compared with palmitoyl pentapeptide-4 (Matrixyl, Pal-KTTKS) which targets pro-collagen I C-terminal peptide signaling, and palmitoyl tetrapeptide-7 (Pal-GQPR) which targets IL-6 and inflammatory pathways, Pal-GHK occupies a distinct mechanistic niche centered on copper-mediated wound signaling and broad ECM remodeling. These lipopeptides are commonly combined in research formulations (e.g., the Pal-GHK + Pal-GQPR "Matrixyl 3000" composition) to engage complementary pathways.

This research preparation is a lipopeptide formulation centered on palmitoyl tripeptide-1 (Pal-GHK), a fatty acid–conjugated derivative of the naturally occurring copper-binding tripeptide glycyl-L-histidyl-L-lysine. Because lipopeptide cosmetic raw materials are often supplied as a defined blend with a carrier glycol and may be combined with related peptides in finished research compositions, individual ingredient specifications are documented below.

*Pal-GQPR is listed only when present in combination formulations such as Matrixyl 3000–type compositions; verify on certificate of analysis.

Physical Characteristics of the Active Ingredient

Because the supplied material may be a defined blend rather than a single molecular entity, no single molecular formula, CAS, or molecular weight is assigned at the product level. Researchers should consult the lot-specific certificate of analysis for the exact composition and active concentration of the material received.

Lipopeptide preparations containing Palmitoyl Tripeptide-1 (Pal-GHK) and related fatty acid-conjugated peptides require careful handling due to their amphiphilic nature. Unlike fully hydrophilic peptides such as GHK or BPC-157, lipopeptides have markedly reduced aqueous solubility and tend to form micelles or aggregates if reconstituted incorrectly. The following protocol is intended for research-laboratory preparation only.

Recommended Reconstitution Protocol:

1. Allow the lyophilized material to equilibrate to room temperature for 20-30 minutes in its sealed vial before opening. This prevents condensation from atmospheric moisture contaminating the powder.
2. Prepare a co-solvent system. Pal-GHK is sparingly soluble in pure water. A typical research stock is prepared by first dissolving the peptide in a small volume of propylene glycol, butylene glycol, or USP-grade ethanol (approximately 10-20% of final volume) to fully wet the lipopeptide.
3. Calculate concentration. For a 10 mg vial intended as a 1 mg/mL stock, add 1 mL of co-solvent followed by aqueous buffer to a 10 mL final volume. For cosmetic research, working concentrations are typically 2-10 ppm (0.0002-0.001% w/v) in the final formulation.
4. Add the aqueous phase slowly (sterile water, PBS, or formulation base) while gently swirling. Rapid water addition can cause precipitation of the palmitoyl chain.
5. Warm gently to 35-40°C in a water bath if cloudiness persists, then mix by gentle inversion. Do not vortex aggressively or sonicate at high power, as this can disrupt the peptide backbone and generate foam that traps active material.
6. Filter-sterilize through a 0.22 μm low-protein-binding (PES) membrane if the stock will be used in cell culture work.

Compound-Specific Handling Notes:

• Lipophilicity: The palmitoyl chain makes the peptide surface-active. Use polypropylene tubes where possible, as the lipopeptide can adsorb to glass and some plastics, reducing effective concentration.
• Oxidation: Pal-GHK contains a histidine imidazole ring that is sensitive to prolonged light exposure. Store working stocks in amber vials or wrap in foil.
• Multi-component blends: When the product is a blend (e.g., with Pal-GQPR or glycerin/water carriers), follow the supplier's batch-specific certificate for the exact reconstitution medium.
• Avoid repeated freeze-thaw of reconstituted stock. Aliquot into single-use volumes.

All weighing, transfer, and reconstitution should be performed in a clean laboratory environment with appropriate PPE. Lipopeptide is supplied for in vitro research and topical-formulation investigation only.

Proper storage of Lipopeptide (Pal-GHK-Lipopeptide) preparations is essential to preserve peptide integrity and avoid hydrolysis of the labile amide bond linking the palmitoyl moiety to the N-terminal glycine. Fatty acid-conjugated peptides are generally more stable than their unconjugated counterparts in the dry state but are subject to ester/amide hydrolysis and lipid oxidation once dissolved.

Lyophilized Powder Storage:

• Long-term storage: Store sealed vials at -20°C in a frost-free freezer. Under these conditions, properly desiccated Pal-GHK and related palmitoyl peptides retain >98% purity for 24-36 months.
• Short-term storage: Refrigeration at 2-8°C is acceptable for up to 30-60 days for actively used vials.
• Transit: The lyophilized form is stable at ambient temperature (room temperature, 18-25°C) for shipping periods of 1-2 weeks without measurable degradation.
• Keep vials tightly sealed and protected from atmospheric moisture. Storage with a desiccant pouch is recommended once the vial is opened.

Reconstituted / Formulated Storage:

• Aqueous or co-solvent stock solutions (1 mg/mL or higher) should be stored at 2-8°C and used within 14-21 days.
• Working dilutions used in cell culture or topical formulation testing should ideally be prepared fresh on the day of use.
• For longer storage, divide stock into single-use aliquots and freeze at -20°C; one freeze-thaw cycle is acceptable, but repeated cycles accelerate degradation.

Compound-Specific Stability Considerations:

• Histidine oxidation: The imidazole side chain of histidine in the GHK motif is susceptible to oxidation, particularly in the presence of trace transition metals. Avoid storing in contact with metal surfaces and consider adding a chelator such as EDTA (0.01-0.05%) to formulation buffers.
• Light sensitivity: Store in amber glass or foil-wrapped containers. UV exposure can drive photo-oxidation of histidine and methionine residues (if present in blend components).
• Palmitoyl chain oxidation: Although saturated, the C16 chain can undergo slow autoxidation. Storage under inert gas (nitrogen or argon overlay) in opened vials extends shelf life.
• pH stability: Pal-GHK is most stable in the pH range 5.0-7.0. Strongly acidic or alkaline conditions accelerate amide bond hydrolysis.

Always refer to the lot-specific Certificate of Analysis for the verified expiration date and purity profile of each batch.